Comparative Efficacy and Safety of Low-dose Fluticasone Propionate and Montelukast in Children with Persistent Asthma

Ostrom, Nancy K.; DeCotiis, Bruce A.; Lincourt, W.; Edwards, Lisa; Hanson, K.M.; Rosenzweig, Jacqueline R. Carranza; Crim, Courtney

doi:10.1016/j.jpeds.2005.03.052

Cited by 88 publications

(73 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Leukotriene modifiers provide clinical benefit in children aged .5 yrs at all levels of severity [170][171][172][173][174] but less than that of low-dose inhaled glucocorticosteroids [175]. Leukotriene modifiers provide partial protection against exercise-induced bronchoconstriction within hours after Growth retardation may be seen with all inhaled glucocorticosteroids when a high dose is administered Growth retardation in both short-and medium-term studies is dose dependent Important differences seem to exist between the growth-retarding effects of various inhaled glucocorticosteroids and inhalers Different age groups seem to differ in their susceptibility to the growth-retarding effects of inhaled glucocorticosteroids; children aged 4-10 yrs are more susceptible than adolescents…”

Section: Inhaled Glucocorticosteroidsmentioning

confidence: 99%

Global strategy for asthma management and prevention: GINA executive summary

Bateman

Ss²,

Barnes³

et al. 2007

Eur Respir J

2,664

2,301

View full text Add to dashboard Cite

Asthma is a serious health problem throughout the world. During the past two decades, many scientific advances have improved our understanding of asthma and ability to manage and control it effectively. However, recommendations for asthma care need to be adapted to local conditions, resources and services. Since it was formed in 1993, the Global Initiative for Asthma, a network of individuals, organisations and public health officials, has played a leading role in disseminating information about the care of patients with asthma based on a process of continuous review of published scientific investigations. A comprehensive workshop report entitled ''A Global Strategy for Asthma Management and Prevention'', first published in 1995, has been widely adopted, translated and reproduced, and forms the basis for many national guidelines. The 2006 report contains important new themes. First, it asserts that ''it is reasonable to expect that in most patients with asthma, control of the disease can and should be achieved and maintained,'' and recommends a change in approach to asthma management, with asthma control, rather than asthma severity, being the focus of treatment decisions. The importance of the patient-care giver partnership and guided self-management, along with setting goals for treatment, are also emphasised.

show abstract

Section: Inhaled Glucocorticosteroidsmentioning

confidence: 99%

Global strategy for asthma management and prevention: GINA executive summary

Bateman

Ss²,

Barnes³

et al. 2007

Eur Respir J

2,664

2,301

View full text Add to dashboard Cite

show abstract

“…46 Less serious side effects of montelukast occur uncommonly, but may include pharyngitis, dizziness, nausea, headache, diarrhea, fever, abdominal pain and rash. 33,36,[41][42][43][44] The incidence of adverse events associated with montelukast is comparable to those of other standard therapies for asthma in childhood and in some studies montelukast was equivalent to placebo. 40 Although FDA approval for montelukast has been obtained for children $2 years of age, safety data to date suggest that this agent may also be used for younger patients between the ages of 6 months and 2 years.…”

Section: Safetymentioning

confidence: 93%

“…33,[36][37][38][39][40][41][42][43][44][45] Serious adverse events, such as worsening asthma, appear to be rare 46 and all reported patients with drug overdoses recovered without sequelae. 46 Less serious side effects of montelukast occur uncommonly, but may include pharyngitis, dizziness, nausea, headache, diarrhea, fever, abdominal pain and rash.…”

Section: Safetymentioning

confidence: 99%

Montelukast Sodium: Administration to Children to Control Intermittent Asthma

2010

Clinical Medicine Reviews in Therapeutics

View full text Add to dashboard Cite

The prototype cysteinyl leukotriene receptor antagonist, montelukast, is generally considered to have a niche application in the chemotherapy of exercise-induced asthma. It has also been used as add-on therapy in patients whose asthma is poorly controlled with inhaled corticosteroid monotherapy, or with the combination of a long-acting β(2)-agonist and an inhaled corticosteroid. Recently, however, montelukast has been reported to possess secondary anti-inflammatory properties, apparently unrelated to conventional antagonism of cysteinyl leukotriene receptors. These novel activities enable montelukast to target eosinophils, monocytes, and, in particular, the corticosteroid-insensitive neutrophil, suggesting that this agent may have a broader spectrum of anti-inflammatory activities than originally thought. If so, montelukast is potentially useful in the chemotherapy of intermittent asthma because most exacerbations of this condition involve respiratory virus infection-triggered inflammatory mechanisms which, to a large extent, involve airway epithelial cell/neutrophil interactions. The primary objective of this review is to evaluate the role of montelukast in the treatment of intermittent asthma in children.

show abstract

“…10,11 However, in direct comparative studies with ICS, LTRAs have been shown to be less effective in improving pulmonary function, asthma symptoms, quality of life, asthma attacks, rescue medication and asthma-related costs in asthmatic children older than 6 years of age. 12,13 A Cochrane review of 27 studies in both children and adults confirmed the superior role of ICS compared to LTRAs in asthma.…”

Section: Commentarymentioning

confidence: 98%

Treatment of preschool asthma with leukotriene receptor antagonists: what's new?

Schayk

2007

Primary Care Respiratory Journal

View full text Add to dashboard Cite

Comparative Efficacy and Safety of Low-dose Fluticasone Propionate and Montelukast in Children with Persistent Asthma

Cited by 88 publications

References 40 publications

Global strategy for asthma management and prevention: GINA executive summary

Global strategy for asthma management and prevention: GINA executive summary

Montelukast Sodium: Administration to Children to Control Intermittent Asthma

Treatment of preschool asthma with leukotriene receptor antagonists: what's new?

Contact Info

Product

Resources

About